Responsibilities
Primarily responsible for the conduct of internal, vendor andinvestigator site audits as assigned by management. Otherresponsibilities include:
Perform audits of complex clinical documents, computer systems,various clinical vendors and investigator sites
Ensures audits are scheduled and conducted per audit schedules
Writes audit reports in English and ensures complete information isincluded so it can be understood by operational teams and senior management
Responsible to participate Investigator Site Audits.
Escalates potential critical/major issues to management in a timely fashion
Point of contact for Contract Auditors, for any audits which need tobe outsourced.
Writes audit reports in a timely fashion, according to SOP requirements.
Meets with operational teams to ensure understanding of the risksassociated with the findings following the audit.
Ensures corrective/preventive actions meet regulatory expectations andare followed to closure.
Supports the development and maintenance of SOPs, forms and templatesto maintain a consistent and compliant QMS.
Assists with training sessions to ensure continued qualification andunderstanding of topics relevant to clinical trials.
Supports Third-Party Audits and Regulatory Inspections.
Participate in process improvement projects and/or other projectsidentified by management.
Qualifications:
Bachelor’s degree, or equivalent is required.
Candidate will have 8 years of Clinical Trial experience within aclinical quality role.
Written and spoken English proficiency is required.
Must be willing and able to travel internationally up to 40%.
Must be fluent in written and spoken Chinese, native speaker preferred(Chinese Auditor positions only).
三叶草生物成立于2007年,是一家处于临床试验阶段的全球生物制药公司,致力于开发新型疫苗和生物疗法,以应对传染性疾病、癌症和自身免疫性疾病。我们自GenHunter授权引进Trimer-Tag?技术平台,一个用于新型疫苗和生物疗法的产品开发平台。我们的研发管线包括六种Trimer-Tag? 亚单位候选疫苗、两种 Trimer-Tag?肿瘤治疗候选产品以及三种 Fc融合蛋白候选产品。应用Trimer-Tag?技术平台,我们已成为新冠疫苗开发企业并研制了“SCB-2019(CpG1018/铝佐剂)”,以应对由SARS-CoV-2(新冠病毒)引起的新冠大流行。基于积极的“SPECTRA”试验数据,三叶草生物有望成为全球范围内通过COVAX机制率先实现重组蛋白新冠疫苗商业化上市的企业之一。
Trimer-Tag?(蛋白质三聚体化)技术平台可以使任意一个目的蛋白三聚体化*,从而可靶向那些天然依赖蛋白质三聚体化功能的疾病生物学靶点,包括数十种包膜RNA 病毒,如冠状病毒、狂犬病毒、呼吸道合胞病毒(RSV)、流感病毒、人类免疫缺陷病毒(HIV)及埃博拉病毒等,以及肿瘤坏死因子(TNF)超家族(TNFSF)的细胞因子。这些肿瘤坏死因子(TNF)超家族(TNFSF)细胞因子具有多种重要生物学功能,并与某些癌症和自身免疫性疾病相关。
Trimer-Tag?是全球一个利用人源三聚体化标签设计及开发共价连接的重组三聚体融合蛋白(三聚体标签蛋白)的技术平台。由Trimer-Tag?开发的三聚体化蛋白对三聚体依赖性疾病靶点具有很强的有效性及良好的安全性。
公司应用Trimer-Tag?(蛋白质三聚体化)技术平台,并凭借自有的生物制药生产能力,搭建研发管线。
扫码下载APP,找工作更方便